Salmonella enterica subsp. I serovars Typhimurium and Enteritidis are major causes of enteric disease. The pathomechanism of enteric infection by serovar Typhimurium has been studied in detail. Serovar Typhimurium employs two pathways in parallel for triggering disease, i.e., the "classical" pathway, triggered by type III secretion system 1 (TTSS-1), and the "alternative" pathway, mediated by TTSS-2. It had remained unclear whether these two pathways would also explain the enteropathogenesis of strains from other serovars. We chose the isolate P125109 of the epidemic serovar Enteritidis PT4/6, generated isogenic mutants, and studied their virulence. Using in vitro and in vivo infection experiments, a dendritic cell depletion strategy, and MyD88 ؊/؊ knockout mice, we found that P125109 employs both the "classical" and "alternative" pathways for triggering mucosal inflammation. The "classical" pathway was phenotypically similar in serovar Typhimurium strain SL1344 and in P125109. However, the kinetics of the "alternative" pathway differed significantly. Via TTSS-2, P125109 colonized the gut tissue more efficiently and triggered mucosal inflammation approximately 1 day faster than SL1344 did. In conclusion, our data demonstrate that different Salmonella spp. can differ in their capacity to trigger mucosal inflammation via the "alternative" pathway in vivo.
Salmonella spp. are a major cause of enteric disease worldwide. In Europe and America, the vast majority of infections are caused by strains of the Salmonella enterica subsp. I serovars Typhimurium and Enteritidis. Both serovars are present in animal flocks (3, 4, 6, 15, 31, 33, 36, 37) . Human infection generally results from the consumption of contaminated foods of animal origin (i.e., it is a zoonosis). Serovars Typhimurium and Enteritidis cause similar disease symptoms in humans, including vomiting, diarrhea, and abdominal pain. Similarly, in a mouse model of enteric infection, strains of both serovars trigger pronounced mucosal inflammation (colitis) by day 3 postinfection (p.i.) (32) . However, the mechanisms triggering the disease in vivo are still poorly understood.
Salmonella enterica subsp. I serovars, including serovars Enteritidis and Typhimurium, share an overall identity of 96% to 99% (12) . Moreover, key virulence determinants, i.e., the Salmonella pathogenicity islands SPI-1, SPI-2, SPI-3, SPI-4, and SPI-5, are conserved between the different S. enterica subsp. I serovars (12) . The virulence function of these pathogenicity islands (and most other virulence factors) has been studied intensively in serovar Typhimurium, i.e., serovar Typhimurium strains SL1344 and ATCC 14028, and in serovar Dublin (18, 34, 35) . However, it had remained unclear whether they would have the same importance in different serovars or other strains or isolates of the same serovar. Therefore, we compared the relative importance for enteropathogenesis of SPI-1 and SPI-2 function between serovar Typhimurium SL1344 and serovar Enteritidis P125109.
Serovar Typhimurium strains SL1344 and ATCC 14028 (and serovar Dublin) have served as model organisms for analyzing the pathomechanisms of enteric Salmonella infection in vivo, i.e., in bovine and mouse models of the disease (16, 24, 35) . Serovar Typhimurium triggers inflammation by using the "classical" and "alternative" pathways in parallel (Fig. 1 ). These pathways differ by their requirement for two main Salmonella virulence systems, the type III secretion systems (TTSS) encoded in SPI-1 (TTSS-1) and SPI-2 (TTSS-2) (Fig. 1 ). (i) The "classical" pathway requires TTSS-1 for invading the gut mucosa and triggering inflammation as soon as 8 to 24 h p.i. Serovar Typhimurium strains lacking TTSS-2 are restricted to this "classical" pathway ( Fig. 1) (10, 11, 18) . (ii) In the "alternative" pathway, dendritic cells (DCs) transport the pathogen into the lamina propria. There, it leaves the DCs, grows within mucosal macrophages, and triggers gut inflammation in a MyD88-dependent way ( Fig. 1) (17) . Serovar Typhimurium mutants lacking TTSS-1 are restricted to the "alternative" pathway and trigger colitis at day 3 p.i. (10, 11, 17, 18) . Serovar Typhimurium strains lacking TTSS-1 and -2 are avirulent. This has established the role of TTSS-1 and TTSS-2 in enteric infection by serovar Typhimurium, i.e., strains SL1344 and ATCC 14028. However, it remained to be demonstrated whether the same two pathways also mediate gut inflammation caused by strains from other S. enterica subsp. I serovars.
In this study, we compared the "classical" (TTSS-1 mediated) and "alternative" (TTSS-2 mediated) pathways of colitis between the serovar Typhimurium strain SL1344 and the sequenced serovar Enteritidis PT4/6 strain P125109. Using equivalent sets of mutants lacking functional TTSS-1 and/or -2, we analyzed tissue culture cell invasion and enteric virulence. In both strain backgrounds, TTSS-1 drove efficient cell invasion and enterocolitis via the classical pathway. Similarly, in both strain backgrounds, TTSS-2 mediated colitis via the alternative pathway. This required DCs and MyD88 signaling in both cases. However, the kinetics differed significantly. Surprisingly, the TTSS-1 mutant of serovar Enteritidis P125109 colonized the mucosal tissue with faster kinetics and had already triggered overt colitis via the "alternative" pathway by day 1 to 2 p.i. Thus, S. enterica subsp. I serovars can differ in the strength and/or efficiency of particular pathways contributing to enteropathogenesis. This may impact therapies aiming at the inhibition of particular virulence pathways and provides a basis for studying why serovar Enteritidis P125109 elicits the "alternative" pathway so efficiently.
MATERIALS AND METHODS
Bacterial strains and plasmids. The naturally streptomycin-resistant wild-type serovar Typhimurium strain SL1344 (19) and a streptomycin-resistant variant of serovar Enteritidis strain P125109 (32) have been described previously. An isogenic TTSS-1 Ϫ mutant of SL1344 (SB566; invC::aphT) has been described previously (14, 28 ). An isogenic TTSS-1 Ϫ mutant of P125109 (M1511; invC::aphT), isogenic TTSS-2 Ϫ mutants of SL1344 (M1516) and P125109 (M1512), and TTSS-1 Ϫ TTSS-2 Ϫ double mutants of SL1344 (M1517) and P125109 (M1513) were generated by P22 transduction of the invC::aphT and/or ssaV::cat allele of SB566 and HH110 (ATCC 14028; ssaV::cat) (14, 28) . M1511 and SB566 were complemented by P22 transduction of the chromosomal wild-type invC region of M1300 (harboring a tetracycline resistance-tagged sipA M45 allele [27] ), yielding M2700 and M2701. The strains are listed in Table 1 . All strains were verified by PCR (presence or absence of mutation) and serotyping (serovar Typhimurium versus serovar Enteritidis).
pM973 expressing green fluorescent protein (GFP) under the control of a TTSS-2 promoter (i.e., after host tissue invasion) was described recently (18) . pDsRed expresses DsRed from the lac promoter. In the gut lumen, DsRed fluorescence is very weak. Once bacteria have entered the gut tissue, DsRed fluorescence is intense and allows enumeration of the bacteria by fluorescence microscopy, as described previously (17) .
Bacteria were grown for 12 h at 37°C in Luria-Bertani broth (LB; with 0.3 M NaCl), diluted 1:20 in fresh medium, and subcultured for 4 h under mild aeration. Bacteria were washed in ice-cold phosphate-buffered saline (PBS). For mouse infections, we used 5 ϫ 10 7 CFU suspended in 50 l of cold PBS, and for tissue culture infections, dilutions in PBS were used, as indicated.
Mice and infection experiments. Infection experiments were carried out in individually ventilated cages as described previously (29) . All mice were specific pathogen free (SPF) and were bred at the Rodent Center HCI, ETH Zürich. This included C57BL/6 mice, B6.129P-CX3CR1 tm1Litt /J mice (20) 7 CFU (by gavage) of the corresponding bacterial strain. Bacterial loads in the cecal lumen, mesenteric lymph nodes (MLNs), liver, and spleen were determined by plating homogenates on MacConkey agar plates as previously described (5) . Animal experiments were approved by Swiss cantonal authorities and performed according to legal requirements.
Histopathological evaluation. Cryosections of cecal mucosa (5 m) were stained with hematoxylin and eosin, and the degree of inflammation was quantified by a pathologist as described previously (29) .
(i) Submucosal edema. Submucosal edema was deduced from the extension of the submucosa and scored by morphometric analysis according to the formula % SE ϭ (b Ϫ a)/c, where % SE is the percentage of submucosal edema, a is the area enclosed by the mucosa (mucosa and intestinal lumen), b is the area enclosed by the borderline between the submucosa and the tunica muscularis (submucosa, mucosa, and intestinal lumen), and c is the area enclosed by the outer edge of the tunica muscularis (tunica muscularis, submucosa, mucosa, and lumen; area of the whole cecal cross section). Submucosal edema was scored as follows: 0, no pathological changes; 1, detectable edema (% SE Ͻ 10%); 2, moderate edema (% SE ϭ 10 to 40%); and 3, profound edema (% SE Ն 40%).
(ii) PMN infiltration into the lamina propria. Polymorphonuclear granulocytes (PMN) in the lamina propria were enumerated in 10 high-power fields (magnification, ϫ400; field diameter, 420 m), and the average number of PMN/high-power field was calculated. The scores were as follows: 0, fewer than 5 PMN per high-power field; 1, 5 to 20 PMN per high-power field; 2, 21 to 60 PMN per high-power field; 3, 61 to 100 PMN per high-power field; and 4, more than 100 PMN per high-power field.
(iii) Goblet cells. The average number of goblet cells per high-power field (magnification, ϫ400) was calculated from 10 different regions of the cecal epithelium and scored as follows: 0, more than 28 goblet cells per high-power field (magnification, ϫ400) (in the ceca of normal SPF mice, we observed an average of 6.4 crypts per high-power field, and the average crypt consisted of 35 to 42 epithelial cells, 25 to 35% of which were differentiated into goblet cells); 1, 11 to 28 goblet cells per high-power field; 2, 1 to 10 goblet cells per high-power field; and 3, less than 1 goblet cell per high-power field.
(iv) Epithelial integrity. Epithelial integrity was scored as follows: 0, no pathological changes detectable in 10 high-power fields (magnification, ϫ400); 1, epithelial desquamation; 2, erosion of the epithelial surface (gaps of 1 to 10 epithelial cells per lesion); and 3, epithelial ulceration (gaps of Ͼ10 epithelial cells per lesion) (at this stage, there is generally granulation tissue below the epithelium).
The combined pathological score for each tissue sample was determined as the sum of these averaged scores, as follows: 0, intestine intact without any signs of inflammation; 1 or 2, minimal signs of inflammation (this was frequently found in the ceca of SPF mice); 3 or 4, slight inflammation; 5 to 8, moderate inflammation; and 9 to 13, profound inflammation.
Immunohistochemistry. Five-micrometer-thick acetone-fixed cryosections were stained as described previously (17), using rat anti-CD11b (M1/70; BMA Biomedicals AG Augst, Switzerland), rat anti-Ly6G (clone RB6-8C5; BD Biosciences Pharmingen), Armenian hamster anti-CD11c monoclonal antibody N418 (HB-224; American Type Culture Collection), or rat anti-CD8 (YTS169) (9) . Goat anti-rat immunoglobulin (Ig; Caltag Laboratories, Burlingame, CA) or goat anti-Armenian hamster Ig (Jackson ImmunoResearch Europe Ltd., Soham, United Kingdom) served as a secondary antibody, and horseradish peroxidasecoupled donkey anti-goat Ig (with 2% normal mouse serum; Jackson ImmunoResearch Europe Ltd., Soham, United Kingdom) served as a tertiary reagent. Slides were developed with amino-ethylcarbazol and counterstained with hemalum.
Analysis of serovar Typhimurium colonization of the lamina propria. Cecal tissue was incubated overnight in PBS with 4% paraformaldehyde at 4°C and then for 8 h in PBS with 20% sucrose at 4°C and was snap frozen in O.C.T. compound (Sakura, Torrance, CA). Twenty-micrometer-thick cryosections were air dried and blocked (PBS with 10% goat serum). GFP-expressing Salmonella spp. harboring pM973 were enumerated in the mucosa as described previously (18) . Briefly, sections were stained with Armenian hamster anti-CD54 antibody (lamina propria staining) (clone 3E2; Becton Dickinson), A647-phalloidin (staining of brush border and cortical actin of individual gut cells; Fluoprobes), and DAPI (4Ј,6-diamidino-2-phenylindole; Sigma Aldrich). Three to nine sections per cecum were analyzed. To analyze the localization of Salmonella spp. harboring pDsRed in CX3CR1 GFP/ϩ -transgenic mice, six nonserial sections (stained with Cy3-conjugated goat anti-Armenian hamster Ig [Jackson ImmunoResearch Laboratories] and DAPI) per mouse were screened by fluorescence microscopy as described previously (17) .
Modified gentamicin protection assay using automated image processing and analysis. HeLa cells were grown in clear-bottomed 96-well plates (Greiner). Salmonella spp. carried the plasmid pM975, encoding GFP under the control of a SPI-2 promoter (26). Strains were cultured for 12 h overnight at 37°C with mild aeration, and 150 l was subcultured in 3 ml of LB medium with 0.3 M NaCl for an additional 4 h. Bacteria were serially diluted in ice-cold Dulbecco's modified Eagle's medium. Cells were infected for 20 min and incubated with gentamicin (400 g/ml) to kill all bacteria that had remained outside host cells. After 4 h, cells were fixed with paraformaldehyde and stained with DAPI. Nine images per well (approximately 6,000 cells) were taken in the GFP and DAPI channels, using a CellWorx automated microscope (API). Image processing was done using CellProfiler (7) and customized Matlab scripts, as described previously (26) . Any cell harboring GFP-expressing bacteria was considered "infected."
Statistical analysis. The exact Mann-Whitney U test was used to perform group comparisons, using SPSS software, version 14.0.
To perform statistical analysis, minimal detectable bacterial colonization levels (CFU) were set to 10 CFU/MLN, 20 CFU/spleen, 60 CFU/liver, and 150 CFU/ cecum in cases where no bacteria were detected by plating. P values of Ͻ0.05 (two-tailed test) were considered statistically significant.
RESULTS
Time course of acute colitis triggered by serovar Enteritidis and Typhimurium mutants lacking functional TTSS-1 and/or TTSS-2. Our previous work demonstrated that wildtype strains of serovars Typhimurium and Enteritidis elicit pronounced acute colitis in streptomycin-pretreated mice. For this study, we extended this analysis by comparing the virulence of isogenic strains of serovars Enteritidis (P125109) and Typhimurium (SL1344) lacking functional TTSS-1 and/or TTSS-2 (termed TTSS-1 Ϫ and TTSS-2 Ϫ strains hereafter) (Table 1).
Streptomycin-pretreated C57BL/6 mice were infected (5 ϫ 10 7 CFU by gavage) with the indicated bacterial strain and analyzed at 1, 2, 3, or 4 days p.i., as indicated (Fig. 2) . Infections with the corresponding wild-type strains and TTSS-1 Ϫ
TTSS-2
Ϫ double mutants served as positive and negative controls. We analyzed bacterial colonization of the cecal lumen, the MLNs, and the spleen and scored the inflammation of the cecal mucosa as described in Materials and Methods.
In line with our previous data, both wild-type strains (P125109 and SL1344) efficiently colonized the intestinal lumen, MLNs, and spleen at days 1 to 2 p.i. In line with earlier data (30), the gut colonization density in wild-type-infected mice dropped at day 2 p.i. and increased again in the subsequent days. This phenomenon is not well understood. The reduced gut colonization levels were more pronounced for wild-type Salmonella spp. than for attenuated mutants (this work; also see reference 30) and might be related to higher gut passage rates or (unidentified) acute defenses. Significant mucosal inflammation was detected as early as day 1 p.i., and the intensity of inflammation increased in both groups until day 3 p.i. In the case of the wild-type serovar Enteritidis strain, we observed a slight drop in gut inflammation at day 4 p.i. This might be attributable to the advanced systemic infection (more spleen colonization). Reduced mucosal inflammation has been observed in mice suffering from severe sepsis (S. Hapfelmeier and W.-D. Hardt, unpublished observations) and might be linked to exhaustion of the immune system.
The TTSS-1 Ϫ TTSS-2 Ϫ double mutants of both strains failed to colonize the spleen and did not elicit cecal inflammation during the course of the experiment. This demonstrated that TTSS-1 and TTSS-2 are key virulence factors for eliciting enteric disease by both strains. Furthermore, we observed that the density of TTSS-1 Ϫ TTSS-2 Ϫ double mutants in the intestinal lumen dropped at days 3 and 4 p.i. This is in line with earlier observations (18, 30) and is attributable to competition with the normal murine gut flora: in the absence of mucosal inflammation, the pathogen can be outcompeted by the regrowing normal gut flora (30) .
The TTSS-2 mutants of serovar Typhimurium SL1344 are known to elicit colitis via the "classical" pathway by day 1 p.i. (18) . We did not observe significant differences between TTSS-2 Ϫ mutants of P125109 and SL1344. Thus, the "classical" pathway seems to operate in a similar fashion in both serovars.
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Typhimurium. Streptomycin-pretreated C57BL/6 mice (n ϭ 5 to 14 animals per group) were infected with the indicated serovar Enteritidis (open circles) or serovar Typhimurium (filled circles) strains. Animals were sacrificed on days 1 to 4 p.i., and we determined the pathology (top row) and the bacterial loads in the cecal lumen (second row), the MLNs (third row), and the spleen (bottom row). The origin of the y axis in every graph represents the detection limit. * , statistically significant difference (P Ͻ 0.05). WT, wild type; re-compl., recomplemented strain. 
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Strikingly, the TTSS-1 Ϫ mutant of P125109 triggered gut inflammation significantly sooner than the TTSS-1 Ϫ mutant of SL1344 (see cecal pathology at day 1 and 2 p.i. [Fig. 2] ). This phenotype could not be explained by different pathogen densities in the gut lumen and was alleviated by recomplementing the chromosomal TTSS-1 mutations in both strains (M2700 and M2701) (Fig. 2) . Thus, P125109 may trigger the "alternative" pathway more efficiently than SL1344 does. This would be in line with the slightly increased kinetics of MLN and spleen colonization observed at days 1 and/or 2 p.i. (Fig. 2) . Furthermore, we confirmed our findings by immunohistological analysis of cecal tissues from mice infected for 2 days with TTSS-1 Ϫ mutants of P125109 and SL1344 (Fig. 3A) . At this time point, the P125109 TTSS-1 Ϫ mutant triggered massive infiltration of Ly6G ϩ (PMN marker), CD11b ϩ (macrophage marker), CD11c ϩ (DC marker), and to a lesser extent, CD8 ϩ (cytotoxic T-cell marker) cells into the cecal mucosa, while the SL1344 TTSS-1 Ϫ mutant did not. In conclusion, TTSS-1 and TTSS-2 are key virulence factors for enteropathogenesis of serovar Enteritidis P125109 and serovar Typhimurium SL1344. TTSS-1-mediated effects were comparable between both strains (Fig. 2) , while TTSS-2-mediated colitis was triggered more efficiently by serovar Enteritidis P125109 (Fig. 2 and 3A) .
Serovar Enteritidis TTSS-1 ؊ mutant reaches higher mucosal tissue loads at day 2 p.i. The serovar Typhimurium TTSS-1 Ϫ strain requires 3 days to reach sufficient gut tissue loads to trigger colitis via the alternative pathway (Ϸ20 bacteria in the lamina propria per tissue section, i.e., Ϸ10 6 CFU/g tissue [17] ). The earlier onset of colitis suggested that serovar Enteritidis P125109 TTSS-1 Ϫ may colonize the gut tissue more efficiently. Thus, streptomycin-pretreated C57BL/6 mice were infected with TTSS-1 Ϫ mutants of serovar Enteritidis P125109 or serovar Typhimurium SL1344 harboring the reporter plasmid pM973 (5 ϫ 10 7 CFU by gavage) for 2 days. The lamina propria loads in the cecum tissue were analyzed by fluorescence microscopy (see Materials and Methods). Serovar Enteritidis P125109 TTSS-1 Ϫ had reached tissue densities of 20 to 120 CFU per tissue section, while serovar Typhimurium SL1344 TTSS-1 Ϫ densities were significantly lower (Fig. 3B) . Thus, efficient lamina propria colonization can explain why serovar Enteritidis P125109 TTSS-1 Ϫ already elicits colitis via the alternative pathway by day 2 p.i.
Equivalent levels of TTSS-1-mediated host cell invasion by serovar Enteritidis P125109 and serovar Typhimurium SL1344. TTSS-1 mediates host cell invasion (25) . Therefore, we performed a host cell invasion assay to further analyze the virulence of the serovar Enteritidis and Typhimurium strains. We recently developed a high-throughput format for quantitative analysis of Salmonella invasion into HeLa cells (26) . In this assay, cells are infected with serovar Enteritidis and Typhimurium strains harboring a plasmid expressing GFP under the control of a SPI-2 promoter (pM975) (see Materials and Methods), and invading bacteria are detected by automated microscopy by virtue of their GFP expression. Using this assay, we found that both wild-type and TTSS-2 Ϫ mutant strains invaded with equivalent efficiencies. In contrast, both TTSS-1 Ϫ mutants and both TTSS-1 Ϫ TTSS-2 Ϫ double mutants did not invade (Fig. 4) . The invasion defect of the TTSS-1 Ϫ mutants could be complemented (Fig. 4) . In conclusion, TTSS-1-mediated virulence, both in vitro and in vivo, was equivalent between serovar Enteritidis strain P125109 and serovar Typhimurium strain SL1344. TTSS-1 ؊ mutants of serovars Enteritidis and Typhimurium show similar DC dependency for enteropathogenesis via the alternative pathway. The TTSS-1 Ϫ mutant of serovar Enteritidis P125109 triggered mucosal inflammation with surprisingly fast kinetics (see above). The mechanism explaining this phenomenon remained to be analyzed. Earlier work by us had established that TTSS-1 Ϫ mutants of serovar Typhimurium SL1344 trigger colitis via the "alternative" pathway and that this pathway strictly requires transepithelial transport facilitated by mucosal DCs and MyD88-dependent signaling by mucosal lymphocytes or leukocytes (17, 18) . However, it remained to be shown whether this also holds true for TTSS-1-defective serovar Enteritidis strains. This was addressed using appropriate mouse lines. To test the requirement for mucosal DCs, we employed a transgenic mouse line (DTR tg ) expressing the primate diphtheria toxin receptor under the control of the CD11c promoter (21) . In the cecal mucosae of these mice, i.p. injection of diphtheria toxin leads to specific depletion of DCs while leaving most other cell populations undisturbed (17) .
Two groups of streptomycin-pretreated mice were infected with the P125109 TTSS-1 Ϫ mutant (5 ϫ 10 7 CFU by gavage). The first group of mice carried the DTR transgene, and DCs were depleted by DTX injection (see Materials and Methods). The second group consisted of littermates lacking the transgene. In the absence of DCs, the P125109 TTSS-1 Ϫ mutant could colonize the intestinal lumen (Fig. 5A ), but it failed to trigger mucosal inflammation (Fig. 5B) . This was in line with earlier data on equivalent serovar Typhimurium strains (17) . Furthermore, spread to the MLNs was significantly impaired in the absence of DCs (Fig. 5A) . These data verified that the TTSS-1 Ϫ mutant of serovar Enteritidis P125109 indeed employed the same "alternative" pathway for eliciting enteropathogenesis as that described earlier for serovar Typhimurium and suggested that it was simply more efficient at doing so.
DC localization of serovar Enteritidis P125109 TTSS-1 ؊ . The serovar Typhimurium TTSS-1 Ϫ mutant localizes in CX3CR1 ϩ DCs at day 1 p.i. and switches to CX3CR1 Ϫ host cells, presumably macrophages, by day 3 p.i. (17) . We analyzed whether this also holds true for serovar Enteritidis P125109 TTSS-1 Ϫ by using CX3CR1 gfp/ϩ mice (20) . These mice express GFP in the cecum lamina propria DCs (17) . Streptomycin-pretreated CX3CR1 gfp/ϩ mice were infected with TTSS-1 Ϫ mutants of serovar Enteritidis P125109 or serovar Typhimurium SL1344 harboring pDsRed (see Materials and Methods). This plasmid yields bright red fluorescence after bacteria have entered the mucosal tissue (17) . By fluorescence microscopy, we found that both strains were localized exclusively in DCs at day 1 p.i. Again, serovar Enteritidis P125109 was present in significantly larger numbers (data not shown). This was in line with the data presented above (Fig. 3B) . At day 2 p.i., 90% of the serovar Enteritidis P125109 TTSS-1 Ϫ bacteria were already located in CX3CR1 Ϫ host cells. In the case of serovar Typhimurium SL1344, this process took 1 day longer (Fig. 6) (17) . The faster relocalization into CX3CR1 Ϫ host cells provided additional evidence for why serovar Enteritidis P125109 triggers the alternative pathway so efficiently.
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The TTSS-1 ؊ mutant of serovar Enteritidis P125109 requires MyD88 to trigger colitis. A second hallmark of the "alternative" pathway is the requirement for MyD88. MyD88 is a central adapter protein that is shared by the interleukin-1 receptor and many Toll-like receptors of the innate immune system (2). Previous work on TTSS-1 Ϫ mutants of serovar Typhimurium established that MyD88 signaling is required for induction of enterocolitis via the alternative pathway, while it is dispensable for the "classical" pathway (18) . Here we analyzed whether the P125109 TTSS-1 Ϫ mutant also requires MyD88 signaling to trigger mucosal inflammation.
Streptomycin-pretreated MyD88 Ϫ/Ϫ mice (C57BL/6 background) and their wild-type (MyD88 ϩ/ϩ ) littermates were infected for 3 days with wild-type P125109 or the isogenic mutants lacking TTSS-1 and/or TTSS-2 function (5 ϫ 10 7 CFU by gavage). Cecal pathology and colonization of the cecal lumen, the MLNs, and the spleen were analyzed. In line with our previous findings for serovar Typhimurium, we observed that the wild-type serovar Enteritidis strain P125109 and the TTSS-2 Ϫ mutant triggered colitis in MyD88 Ϫ/Ϫ and wild-type mice alike (P Ͼ 0.05) (Fig. 7A) . In contrast, the TTSS-1 Ϫ mutant of P125109 triggered colitis in wild-type but not in 
MyD88
Ϫ/Ϫ mice. Thus, the TTSS-1 Ϫ mutant of P125109 triggers colitis in a MyD88-dependent fashion. Therefore, we concluded that it employs the "alternative" pathway, as outlined in Fig. 1 . Nevertheless, it did so with faster kinetics than equivalent serovar Typhimurium SL1344 mutants (Fig. 2) (17, 18) . We speculate that this strain may express features which are missing from serovar Typhimurium SL1344 (e.g., an additional TTSS-2 effector protein may be present in strain P125109). These hypothetical features might enhance DC-mediated transport or protect serovar Enteritidis P125109 (but not serovar Typhimurium SL1344) from innate immune defenses in the gut mucosa and thereby enhance the kinetics of mucosa colonization and trigger mucosal inflammation via this pathway.
DISCUSSION
Earlier work established that TTSS-1 and TTSS-2 play key functions in serovar Typhimurium enteropathogenesis. Here we employed the serovar Enteritidis strain P125109 to show that the same can hold true for strains from other serovars. A TTSS-2 Ϫ mutant of P125109 triggered colitis via the "classical" pathway ( Fig. 1) . Tissue culture cell invasiveness and all features of enteropathogenesis were very similar between this mutant and the equivalent serovar Typhimurium SL1344 TTSS-2 Ϫ mutant. This suggested that TTSS-1-mediated enteropathogenesis is quite similar between both strains. It remains to be shown whether the same holds true for other strains of these serovars. In contrast, the kinetics of the "alternative" pathway differed significantly between the two strains analyzed. The TTSS-1 Ϫ mutant of P125109 triggered mucosal inflammation approximately 1 day faster than the equivalent serovar Typhimurium mutant. Nevertheless, the requirement for mucosal DCs and for MyD88 signaling confirmed that the basic mechanisms leading to colitis were conserved between both strains.
Why is the "alternative" pathway of enteropathogenesis so efficient in serovar Enteritidis P125109? Our earlier data on serovar Typhimurium strains showed that the "alternative" pathway involves several steps, i.e., DC-mediated transport into the lamina propria, leaving the DCs, entering CD11b ϩ
CX3CR1
Ϫ CD11c Ϫ mucosal macrophages, and growing to densities of 10 5 to 10 6 bacteria per gram of tissue, before inflammation is triggered via MyD88-dependent pathways (17, 18) . Therefore, it seems likely that P125109 TTSS-1 Ϫ is particularly efficient in at least one of these steps. This would be in line with the higher lamina propria loads observed at day 2 p.i., with the faster relocalization to CX3CR1
Ϫ cells, and with the slightly enhanced efficiency of P125109 TTSS-1 Ϫ at colonizing MLNs and the spleen at days 1 and 2 p.i. It is unknown whether these observations are attributable to enhanced expression of TTSS-2 (or TTSS-2 effector proteins) or the presence of additional virulence factors in P125109 which are absent from serovar Typhimurium SL1344. At least the TTSS-2 apparatuses, encoded within SPI-2, seem to be virtually identical between serovars Enteritidis and Typhimurium, as indicated by a pairwise nucleotide BLAST analysis (98 to 99% identity; NCBI tools). Identifying the molecular basis of the fast kinetics of the "alternative" pathway of serovar Enteritidis P125109 will be an interesting subject for future research.
Some evidence suggests that serovar Enteritidis may indeed express additional virulence factors protecting it from MyD88-dependent defenses. TlpA (for TIR-like protein A), a protein with homology to Toll/interleukin-1 receptor (TIR) domains of Toll-like receptors, was discovered in the serovar Enteritidis genome but is lacking in serovar Typhimurium SL1344 (23) . TlpA overexpression can suppress Toll-like receptor/MyD88- tg mice (open circles; n ϭ 8 mice) and wild-type littermates (filled circles; n ϭ 7 mice) were pretreated with streptomycin. DTX was administered to both groups, 1 day before and 1 day after infection with the TTSS-1 Ϫ mutant of serovar Enteritidis P125109. Mice were sacrificed at day 3 p.i., and cecal pathology (B) and colonization levels in the cecal lumen, the MLNs, the spleen, and the liver (A) were analyzed. * , statistically significant difference (P Ͻ 0.05).
FIG. 6. DC localization of serovar Enteritidis P125109 TTSS-1
Ϫ . Streptomycin-pretreated CX3CR1 gfp/ϩ mice (n ϭ 5) were pretreated with streptomycin and infected with the indicated Salmonella strains harboring pDsRed. At day 1 or 2 p.i., localization in CX3CR1
ϩ DCs or CX3CR1
Ϫ cells of the lamina propria (Lp) was analyzed by fluorescence microscopy (see Materials and Methods) (six cecum tissue sections per mouse).
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dependent signaling, and tlpA mutants have a growth defect in macrophages and reduced virulence in systemic mouse infections (23) . Two additional TIR domain-containing proteins, namely, TcpC and TcpB, were identified recently in uropathogenic Escherichia coli and Brucella melitensis (8) . These proteins interact directly with MyD88 and inhibit MyD88-dependent proinflammatory signaling. The presence of TlpA, TcpB-like proteins, or similar inhibitors of innate immune defenses might explain why serovar Enteritidis P125109 grows particularly well within lamina propria cells. This might explain the fast kinetics of the "alternative" pathway observed with P125109 TTSS-1 Ϫ . Future work will have to elucidate further the molecular and cellular mechanisms underlying this hypothesis.
In conclusion, different Salmonella spp. can vary in their capacity to trigger mucosal inflammation via the "alternative" pathway. The same might well hold true for the "classical" pathway (13, 22, 38) . These differences can only be revealed by a detailed analysis of each particular strain, as demonstrated here. This type of data will advance our understanding of the mechanisms contributing to enteric disease. Moreover, it will reveal possible critical checkpoints encountered by the pathogen during the course of disease. These critical checkpoints may represent promising starting points for the development of new effective therapies.
